Chemistry Reference
In-Depth Information
45. Roy A, Pahan K. Prospects of statins in Parkinson disease. Neuroscientist 2011;17:
244-255.
46. Tang TT, Song Y, Ding YJ, Liao YH, Yu X, Du R, Xiao H, Yuan J, Zhou ZH,
Liao MY, Yao R, Jevallee H, Shi GP, Cheng X. Atorvastatin upregulates regulatory
T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J.
Lipid Res. 2011;52:1023-1032.
47. Casirola DM, Ferraris RP. Alpha-glucosidase inhibitors prevent diet induced increases
in intestinal sugar transport in diabetic mice. Metabolism 2006;55:832-841.
48. Van de Laar F. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.
Vasc. Health Risk Manag. 2008;4:1189-1195.
49. Geng P, Qiu F, Zhu Y, Bai G. Four acarviosin-containing oligosaccharides iden-
tified from
Streptomyces coelicoflavus
ZG0656 are potent inhibitors of
α
-amylase.
Carbohydr. Res. 2008;343:882-892.
50. Deppenmeier U, Hoffmeister M, Prust C. Biochemistry and biotechnological appli-
cations of
Gluconobacter
strains. Appl. Microbiol. Biotechnol. 2002;60:233-242.
51. Camerino M, Thompson P, Chalmer D. New drugs for diabetes: the design and
molecular modelling of
α
-amylase peptidomimetics. Proc. 4th Int. Peptide Symp.
Australian Peptide Association, Australia, 2007. pp. 1-2.
52. Heyl DL, Fernandes S, Khullar L, Stephens J, Blaney E, Opang-Owusu H, Stahelin B,
Pasko T, Jacobs J, Bailey D, Brown D, Milletti MC. Correlation of LUMO localization
with the alpha-amylase inhibition constant in a tendamistat-based series of linear and
cyclic peptides. Bioorg. Med. Chem. 2005;13:4262-4268.
53. Heyl DL, Tobwala S, Lucas LS, Nandanie AD, Himm RW, Kappler J, Blaney EJ,
Groom J, Asbill J, Nzoma JK, Jarosz C, Palamma H, Schullery SE. Peptide inhibitors
of
α
-amylase based on tendamistat: development of analogues with
ϕ
-amino acids
linking critical binding segments. Prot. Pept. Lett. 2005;12:275-280.
54. Rehm S, Han S, Hassani I, Sokocevic A, Jonker HRA, Engels JW, Schwalbe H. The
high resolution NMR structure of parvulustat (Z-2685) from
Streptomyces parvulus
FH-1641: comparison with tendamistat from
Streptomyces tendae
4158. Chem. Biol.
Chem. 2009;10:119-127.
55. Souren P, Hou CT, Kang SC.
-Glucosidase inhibitory activities of 10-hydroxy-8(
E
)-
octadecenoic acid: an intermediate of bioconversion of oleic acid to 7,10-dihydroxy-
8(
E
)-octadecenoic acid. New Biotechnol. 2010;27:419-423.
56. Wu M, Singh SB, Wang J, Chung CC, Salituro S, Karanam VB, Lee SH, Powles
M, Ellsworth KP, Lassman ME, Miller C, Myers RW, Tota MR, Zhang BB, Li
C. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS)
inhibitor platensimycin in mouse models of diabetes. Proc. Natl. Acad. Sci. U.S.A.
2011;108:5378-5383.
57. Kahan BD. Forty years of publication of transplantation proceedings—the second
decade: the cyclosporine revolution. Transplant Proc. 2009;41:1423-1437.
58. Bentley R. Mycophenolic acid: a one hundred year odyssey from antibiotic to
immunosuppressant. Chem. Rev. 2000;100:3801-3825.
59. Sneader W. Drug Discovery: A History. 2005. John Wiley and Sons, Ltd., England.
60. Strader CR, Pearce CJ, Oberlies NH. Fingolimod (FTY720): a recently approved
multiple sclerosis drug based on a fungal secondary metabolite. J. Nat. Prod. 2011;74:
900-907.
α
